期刊
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
卷 38, 期 1, 页码 309-318出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2022.2150186
关键词
Ornithine decarboxylase; Dimethyl sulfoxide; cucurbit[6]uril; trans-4-(4-(dimethylamino)-styryl)-1-methylpyridinium iodide; high-throughput screening assay
Ornithine decarboxylase (ODC), a key enzyme in polyamine synthesis, is a therapeutic target for cancer and Alzheimer's disease (AD). We report a DMSO-tolerant ODC assay that overcomes the limitations of dimethyl sulfoxide (DMSO) in high-throughput screening (HTS). Furthermore, we optimized ODC production in human cell lines for HTS. Our newly developed assay represents a crucial first step in discovering more effective ODC modulators.
Ornithine decarboxylase (ODC), the first rate-limiting enzyme in polyamine synthesis, has emerged as a therapeutic target for cancer and Alzheimer's disease (AD). To inhibit ODC, alpha-difluoromethylornithine (DFMO), an irreversible ODC inhibitor, has been widely used. However, due to its poor pharmacokinetics, the need for discovery of better ODC inhibitors is inevitable. For high-throughput screening (HTS) of ODC inhibitors, an ODC enzyme assay using supramolecular tandem assay has been introduced. Nevertheless, there has been no study utilising the ODC tandem assay for HTS, possibly due to its intolerability to dimethyl sulfoxide (DMSO), a common amphipathic solvent used for drug libraries. Here we report a DMSO-tolerant ODC tandem assay in which DMSO-dependent fluorescence quenching becomes negligible by separating enzyme reaction and putrescine detection. Furthermore, we optimised human cell-line-based mass production of ODC for HTS. Our newly developed assay can be a crucial first step in discovering more effective ODC modulators than DFMO.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据